Menu Search
Equities

Healios KK

4593:TYO

Healios KK

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)259.00
  • Today's Change18.00 / 7.47%
  • Shares traded6.87m
  • 1 Year change+14.60%
  • Beta1.0723
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Healios KK grew revenues 34.44% from 90.00m to 121.00m while net income improved from a loss of 5.17bn to a smaller loss of 3.82bn.
Gross margin85.06%
Net profit margin-1,030.65%
Operating margin-604.41%
Return on assets-33.11%
Return on equity-166.07%
Return on investment-49.17%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Healios KK fell by 525.00m. Cash Flow from Financing totalled 3.34bn or 2,757.85% of revenues. In addition the company used 2.82bn for operations while cash used for investing totalled 1.12bn.
Cash flow per share-63.86
Price/Cash flow per share--
Book value per share36.00
Tangible book value per share-13.09
More ▼

Balance sheet in JPYView more

Healios KK has a Debt to Total Capital ratio of 74.69%, a lower figure than the previous year's 182.43%.
Current ratio1.39
Quick ratio--
Total debt/total equity2.97
Total debt/total capital0.7469
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.